

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (1/98)

Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. **IAM 467 PA**

First Inventor or Application Identifier **Michael G. Hayek**

Title **LUTEIN-CONTAINING SUPPLEMENT AND PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS**

Express Mail Label No. **EJ148049005US**

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages **26**]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **17**]
4. Oath or Declaration [Total Pages **2**]
  - a. ☒ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 17 completed)  
(Note Box 5 below)
    - i. ☐ DELETION OF INVENTOR(S).  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. §3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ \*Small Entity Statement(s) ☐ Statement filed in prior application (PTO/SB/09-12) ☐ Status still proper and desired
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Other: **Check \$916.00 (filing fee)**

\* A new statement is required to be entitled to pay small entity fees, except where one has been filed in a prior application and is being relied upon.

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No:

Prior application information: Examiner \_\_\_\_\_

Group / Art Unit: \_\_\_\_\_

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

or ☒ Correspondence address below

(Insert Customer No. or Attach bar code label here):

Name	<b>Susan M. Luna</b>				
	<b>Killworth, Gottman, Hagan &amp; Schaeff, L.L.P</b>				
Address	<b>One Dayton Centre</b>				
	<b>One South Main Street, Suite 500</b>				
City	<b>Dayton</b>	State	<b>OH</b>	Zip Code	<b>45402-2023</b>
Country	<b>United States</b>	Telephone	<b>937-223-2050</b>	Fax	<b>937-223-0724</b>

Name (Print/Type)	<b>Susan M. Luna</b>	Registration No. (Attorney/Agent)	<b>38,769</b>
Signature	<i>Susan M. Luna</i>	Date	<b>4/13/99</b>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

## LUTEIN-CONTAINING SUPPLEMENT AND PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS

### CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application Serial No. 60/081,968,  
5 filed April 16, 1998.

### BACKGROUND OF THE INVENTION

This invention relates to a pet food supplement and process for enhancing immune  
response and improving the overall health of companion animals such as cats and dogs, and more  
particularly, to a pet food supplement and process which includes beneficial amounts of lutein in  
10 the animal's diet.

Carotenoids are naturally-occurring plant pigments which are absorbed in varying degrees  
by different species. Common carotenoids include  $\beta$ -carotene, lycopene, astaxanthin, and  
canthaxanthin. These carotenoids are known to play an important role in modulating the immune  
system and enhancing the health of these species. For example, canthaxanthin has been found to  
15 prevent chemical-induced carcinogenesis in mice while  $\alpha$ -carotene has been found to inhibit  
human neuroblastoma cell proliferation. Canthaxanthin has also been found to increase  
lymphocyte proliferation in rats and enhance the production of tumor necrosis factor (TNF) by  
macrophages in hamsters. Astaxanthin and  $\beta$ -carotene have been found to increase ex vivo  
antibody response of mouse splenocytes to T-dependent antigens. However, the majority of  
20 studies to date have focused on the effects of  $\beta$ -carotene.

Few studies have been conducted with regard to the physiologic function of lutein, a major  
blood carotenoid in some species (human, chicken). In some recent studies, it has been found that  
dietary lutein decreases mammary tumor incidence, tumor growth and has shortened tumor  
latency in mice challenged with a transplantable murine mammary tumor cell line. Dietary lutein  
25 was also found to enhance lymphocyte proliferation in mouse splenocytes. Splenocytes from mice  
injected peritoneally with lutein, astaxanthin, and  $\beta$ -carotene have shown enhanced antibody

response to T-dependent antigens. Therefore, carotenoids including lutein possess immuno-modulatory activities and may be important in disease etiology.

Accordingly, there is still a need in the art for promoting a healthy immune system in companion animals such as dogs and cats.

### SUMMARY OF THE INVENTION

The present invention meets that need by providing a process for feeding a companion animal such as a dog or cat a diet containing an effective amount of lutein to enhance immune response and improve the overall health of the animal. Preferably, the animal is fed a diet which includes from about 1 to about 50 mg/day of lutein (from about 2 to about 315 mg lutein/kg diet). Such a diet provides sufficient lutein to be absorbed by the animal and supplied to the blood and blood leukocytes and neutrophils in the animal.

The lutein is preferably provided in a dietary supplement for the animal which comprises, on a dry matter basis, from about 0.001 to about 2% by weight lutein. Where the companion animal is a dog, the supplement preferably comprises from about 0.01% to about 1% by weight lutein. Where the companion animal is a cat, the supplement preferably comprises from about 0.01% to about 1% by weight lutein.

Accordingly, it is a feature of the present invention to provide a pet food supplement and process for enhancing immune response and improving the overall health of companion animals such as dogs and cats by providing an effective amount of lutein in the diet of the animal. This, and other features and advantages of the present invention, will become apparent from the following detailed description, the accompanying drawings, and the appended claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph of concentration of blood plasma lutein in dogs (nmol/L) versus time;

Fig. 2 is a graph of DTH response in dogs fed lutein daily for 6 weeks;

Fig. 3 is a graph of DTH response in dogs fed lutein daily for 12 weeks;

Fig. 4 is a graph of PHA-stimulated PBMC response in dogs fed lutein daily for 12 weeks;

Fig. 5 is a graph of Con A-stimulated PBMC response in dogs fed lutein daily for 12 weeks;

Fig. 6 is a graph of PWM-stimulated PBMC response in dogs fed lutein daily for 12 weeks;

5 Fig. 7 is a graph of the effect of dietary lutein on the percentages of CD4+ T-helper cells and CD8+ T-cytotoxic cells in dogs fed lutein daily for 12 weeks;

Fig. 8 is a graph of the effect of dietary lutein on the percentages of CD5+ cells and MHC II+ cells in dogs fed lutein daily for 12 weeks;

10 Fig. 9 is a graph of concentrations of plasma polyclonal IgG and IgM in dogs fed lutein daily for 17 weeks;

Fig. 10 is a graph of concentration of blood plasma lutein in cats ( $\mu\text{mol/L}$ ) versus time;

Fig. 11 is a graph of Con A-stimulated PBMC response in cats fed lutein daily for 12 weeks;

15 Fig. 12 is a graph of PWM-stimulated PBMC response in cats fed lutein daily for 12 weeks;

Fig. 13 is a graph of DTH response in cats fed lutein daily for 6 weeks;

Fig. 14 is a graph of DTH response in cats fed lutein daily for 12 weeks;

Fig. 15 is a graph of the effect of dietary lutein on the percentages of CD3+ T cells and CD21+ B cells in cats fed lutein daily for 12 weeks;

20 Fig. 16 is a graph of the effect of dietary lutein on the percentages of CD4+ T-helper cells and CD8+ T-cytotoxic cells in cats fed lutein daily for 12 weeks; and

Fig. 17 is a graph of concentrations of plasma polyclonal IgG in dogs fed lutein daily for 12 weeks.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

25 The present invention uses a pet food composition which contains a source of lutein as a supplement in an amount between about 1 to 50 mg/day of lutein (from about 2 to about 315 mg lutein/kg diet). Such a diet provides sufficient lutein to be absorbed by the animal and supplied to

the blood and blood leukocytes and neutrophils in the animal. Both domestic dogs and cats are able to absorb dietary lutein. Furthermore, circulating lutein is significantly absorbed by both peripheral blood lymphocytes and neutrophils in such animals. Lutein is also distributed in the various subcellular organelles. Such lutein in the various organelles of leukocytes is believed to (1) protect these cells from oxygen free radical attack and/or (2) directly regulate nuclear events. Thus, feeding companion animals such as dogs and cats effective amounts of lutein provides lutein at important cellular sites in the body tissues of the animal which results in an up-regulation of immune function and improved health in such animals.

The pet food composition can be any suitable pet food formula which also provides adequate nutrition for the animal. For example, a typical canine diet for use in the present invention may contain about 20 to 40% crude protein, about 4 to 30% fat, and about 4 to 20% total dietary fiber. However, no specific ratios or percentages of these or other nutrients are required. The lutein may be blended with such pet food to provide the beneficial amounts needed.

In order that the invention may be more readily understood, reference is made to the following examples which are intended to illustrate the invention, but not limit the scope thereof.

#### Example 1 - Lutein Uptake in Dogs

Fifty six female Beagle dogs (17 to 18 months old; average body weight  $11.4 \pm 0.4$  kg) were randomly assigned to be supplemented daily with 0, 5, 10 or 20 mg lutein for 17 weeks. The lutein contained 76.66% lutein and 5.23% zeaxanthin. The lutein supplement was resuspended in soybean oil to the appropriate concentration and 1 mL administered perorally at 0800 h daily. Food (200 g/dog/d) was offered immediately after the lutein supplementation. The basal diet shown in Table 1 below met or exceeded the requirements for all essential nutrients (NRC 1985).

Table 1

Component	Composition (g/kg)
Moisture	66
Protein	262
Ash	74
Fat	160
Calcium	14.8
Phosphorus	10.3
Gross Energy (kcal/kg)	4783

All dogs were housed in 2 x 2 m pens (2 dogs/pen) in a temperature (20 to 22°C) and light (14 h light) controlled facility. Body weight was recorded at weeks 0, 6, and 12.

Blood was collected by jugular venipuncture into heparinized evacuated tubes on weeks 0, 2, 4, 8 and 12 and aliquots used for HPLC analysis and for assessing immune responses.

#### Extraction and HPLC analysis

Plasma was extracted for analysis of lutein, zeaxanthin, retinol and  $\alpha$ -tocopherol. Briefly, plasma protein was precipitated by adding an equal volume of ethanol containing 0.1 % butylated hydroxytoluene (BHT) (Aldrich Chemical Co., Milwaukee, WI). The mixture was extracted with 5 mL of a 1:1 mixture of petroleum ether:anhydrous diethyl ether.

The dried residue was resuspended in mobile phase consisting of a 47:47:6 (v:v:v) mixture of HPLC-grade acetonitrile: methanol: chloroform (Fisher Scientific, Fair Lawn, NJ). Lutein, zeaxanthin and  $\alpha$ -tocopherol were quantitated by comparing the area under the curve whereas retinol was quantitated using peak height. The identity of the eluted compounds was confirmed

by comparing their absorption spectrum with that of pure standards. Because baseline separation of lutein and zeaxanthin was not accomplished, plasma concentrations were reported as lutein + zeaxanthin.

#### Delayed type hypersensitivity response

Skin induration response was assessed in all dogs on weeks 0, 6, and 12. Dogs were injected intradermally in the flank area with saline (8.5 g/L; control), an attenuated polyvalent vaccine containing canine distemper virus, canine adenovirus type-2, canine parainfluenza virus and parvovirus (Vanguard 5, Smithkline Beecham, West Chester, PA; specific antigen), and PHA (0.5 g/L; nonspecific antigen). The doses of vaccine and PHA used were previously determined to provide optimal skin response in Beagle dogs of similar age. The injection site was clipped and wiped with 70 % ethyl alcohol. The injection volume was 100  $\mu$ L. Skin induration was measured at 0, 24, 48 and 72 h post-injection with the aid of a pressure-sensitive digital micrometer (Mitsutoyo, Tokyo, Japan) and response was expressed as a percentage of skin thickness measured at 0 h.

#### Lymphocyte proliferation

Blood collected on weeks 0, 2, 4, 8 and 12 were used to assess mitogen-induced lymphocyte proliferation by peripheral blood mononuclear cells (PBMC). Whole blood culture was used in order to mimic in vivo conditions. Mitogens used were phytohemagglutinin (PHA), concanavalin A (Con A) and pokeweed mitogen (PWM). Whole blood was thoroughly mixed and then diluted 1: 12 with RPMI-1640 containing 25 mM of Hepes, penicillin (100 U/mL) and streptomycin (100  $\mu$ g/mL) (Sigma, St. Louis, MO). Preliminary studies using undiluted blood and blood diluted 1:2, 1:4, 1:8, 1:12 and 1:16 showed optimal PBMC proliferative response with a 1:12 dilution. Triplicate 150  $\mu$ L volumes were pipetted into 96-well round bottom plates and 50  $\mu$ L of the appropriate mitogens added. The final concentrations of the mitogens in culture were 2 and 10  $\mu$ g/mL for PHA, 1 and 5  $\mu$ g/mL for Con A and 0.5 and 2.5  $\mu$ g/mL for PWM. The two mitogen concentrations gave maximum (the higher mitogen concentration) and suboptimal (lower mitogen concentration) proliferative responses in preliminary studies using blood from

similar animals. The mixture was incubated for 72 h at 37°C in a humidified incubator under a 5 % CO<sub>2</sub> atmosphere. Four hours prior to the termination of the incubation period, 20 µL of [<sup>3</sup>H]-thymidine (1 [µCi/well]) were added. Cells were harvested onto fiberglass filters and radioactivity was counted by liquid scintillation. Proliferation response of PBMC was expressed as stimulation index (cpm of stimulated cultures/cpm of unstimulated cultures).

#### Lymphocyte subsets

Blood leukocytes were separated using Histopaque-1119 (Sigma, St. Louis, MO). Cells were washed three times with phosphate-buffered saline (PBS, pH 7.4) and contaminating erythrocytes were lysed in NH<sub>4</sub>Cl (8.4 g/L). Lymphocyte subsets were determined by flow cytometry (FACScan, Becton Dickinson, San Jose, CA). Isolated mononuclear cells were resuspended to 1 x 10<sup>7</sup> cells/mL in PBS supplemented with 2 % gamma globulin-free serum, 5 % goat serum and 0.2 g/L sodium azide. For immunofluorescence analysis, a total of 5 x 10<sup>5</sup> cells were incubated for 30 minutes on ice with optimal concentrations of mouse anti-canine monoclonal antibody (mAb). The mAb used were specific for the following lymphocyte subsets: total T cells (anti-CD5), T-helper cells (anti-CD4), T-cytotoxic/suppressor cells (anti-CD8), lymphocytes expressing major histocompatibility complex (MHQ class II antigens (anti-MHC class II), and B cells (anti-CD21). Cells were then washed three times and incubated with a secondary antibody, fluorescein isothiocyanate (FITC)-conjugated goat F(ab')<sub>2</sub> anti-mouse IgG+IgM (H+L) (Caltag, Burlingame, CA), for 30 minutes on ice to visualize the bound mAb. Stained cells were fixed in 4 % paraformaldehyde in preparation for acquisition.

Appropriate negative controls were included to correct for background fluorescence. Data were expressed as the percentage of positive-staining cells corrected for cells stained nonspecifically with the secondary antibody.

#### NK Cell Cytotoxicity

Canine thyroid adenocarcinoma cells were used as target cells in assessing NK cell cytotoxic activity. This cell line was previously shown to be susceptible to killing by canine NK



cell. Target cells were cultured in a T75 flask with 20 mL minimum essential medium (MEM; Sigma Chem. Co., St. Louis, MO) supplemented with 10 % fetal calf serum (FCS), 100 U/mL of penicillin and 100 µg/mL of streptomycin. When confluent, target cells were trypsinized, washed 3 times and resuspended to  $5 \times 10^5$  cells/mL in complete medium (RPMI- 1640 + 10 % FCS + 100 U/mL of penicillin + 100 µg/mL of streptomycin). Triplicate 100 µL aliquots of the target cells were pipetted into 96-well U-bottom plates (Costar, Cambridge, MA) and incubated for 8 hours to allow cell adherence. Lymphocytes (effector cells; 100 µL) isolated by percoll separation (as described above) were then added to the target cells to provide an effector:target cell (E:T) ratio of 10:1. After 10 hours of incubation at 37°C, 20 µl of a substrate containing 5 µg of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added. The mixture was incubated for 4 hours at 37°C after which the unmetabolized MTT was removed by aspiration. The formazan crystals were dissolved by adding 200 µL of 95 % ethanol. Optical density was measured at 570 nm using a microplate reader. The percentage of NK cell-specific lysis was calculated as follows:

$$\text{Specific cytotoxicity (\%)} = 100 \times \{1 - [(\text{OD of target cells and effector cells} - \text{OD of effector cells}) / (\text{OD of target cells})]\}$$

### IL-2 production

Whole blood was diluted 1:2 with RPMI-1640 supplemented with Hepes and antibiotics (described earlier) and 400 µL of diluted blood were pipetted into 48-well plates (Costar, Cambridge, MA). Cells were stimulated with PHA (400 µL of a 5 µg/mL solution) for 48 hours at 37°C in a 5 % CO<sub>2</sub> atmosphere. The plates were centrifuged at 200 x g for 10 minutes and the supernatant was frozen at -80°C. The IL-2 content of the culture supernatant was determined in triplicate by ELISA (Intergen, Purchase, NY). The polyclonal anti-human IL-2 cross-reacted with canine IL-2 and recombinant human IL-2 was used as the standard.

### Serum IgG and IgM

Serum collected on weeks 0, 2, 4, 8 and 12 were analyzed for IgG and IgM concentrations by single radial immunodiffusion (SRID). In addition, all dogs were vaccinated with the polyvalent vaccine (Vanguard 5, Smithkline Beacham, West Chester, PA) on week 13 and again on week 15 to study the possible anamnestic effect of dietary lutein. Blood was collected weekly from week 13 through week 17. Goat antiserum to canine IgG (10 %, whole molecule) or IgM (7.5 %,  $\mu$  chain specific) (ICN, Aurora, OH) was mixed with melted agarose (10 g/L in PBS; Sigma Chem. Co., St. Louis, MO) and the mixture solidified in SRID plates. Duplicate 5  $\mu$ L volumes of serum or IgG (0, 2.88, 5.75, 11.5 and 23.0 mg/ml) or IgM (0, 0.25, 0.5, 1.0 and 2.0 mg/ml) standard were loaded into the wells. After incubating for 24 hours at room temperature in a humidified chamber, ring diameters were measured using a SRID reader (Transidyne General Corp., Ann Arbor, MI).

### Lipid peroxidation (TBARS) assay

Plasma lipid peroxidation activity was determined by measuring malondialdehyde (MDA) production. The standard used was 1,1,3,3-tetramethoxypropane JMP) (Sigma Chem. Co., St. Louis, MO). Duplicate 500  $\mu$ L plasma samples were pipetted into 15 ml, glass tubes and 3 mL of 10 g/L phosphoric acid and 1 ml of 6 g/L TBA solution were added. The mixture was boiled in a water bath for 45 minutes. Tubes were allowed to cool and the TBA-MDA complex was extracted with 4 ml of n-butanol. The butanol layer was separated by centrifugation at 1,000 x g for 10 minutes and absorbance was measured on at 532 nm (Beckman, Fullerton, CA). The TBARS activity was expressed in nmole MDA/L plasma.

### Statistics

Data were analyzed by split-plot ANOVA using the General Linear Model of SAS. The statistical model was  $Y_{ijk} = \mu + \text{Diet}_i + \text{Dog}_j(\text{Diet}) + \text{Period}_k + \text{Diet}_i * \text{Period}_k + e_{ijk}$ . Differences among treatment means were compared using orthogonal contrast and were considered statistically significant when  $P < 0.05$ .

## RESULTS

### Body weight

Dietary lutein did not significantly affect changes in body weight during the experimental period as shown below in Table 2. Body weight across all diets and periods averaged  $11.4 \pm 0.4$  kg.

Table 2

Average body weight (kg) of dogs supplemented daily with 0, 5, 10 or 20 mg lutein<sup>1</sup>

Week	Dietary lutein, mg/d			
	0	5	10	20
0	$11.7 \pm 0.3$	$11.2 \pm 0.4$	$11.6 \pm 0.5$	$11.2 \pm 0.3$
6	$11.0 \pm 0.3$	$11.0 \pm 0.3$	$11.5 \pm 0.3$	$10.9 \pm 0.3$
12	$12.1 \pm 0.4$	$11.7 \pm 0.4$	$11.8 \pm 0.4$	$11.6 \pm 0.3$

<sup>1</sup>Values are means  $\pm$  SEM (n = 14/diet/period). There was no significant treatment difference in body weight within a sampling period as analyzed by repeated measures ANOVA.

### Plasma

Plasma concentrations of lutein + zeaxanthin in lutein-supplemented dogs increased rapidly after 2 weeks of feeding (Figure 1). Plasma concentrations continued to increase thereafter, although more gradually, in dogs fed 10 and 20 mg lutein. In contrast, plasma lutein + zeaxanthin was not detectable in unsupplemented dogs. Concentrations of plasma lutein + zeaxanthin on weeks 2 through 12 was significantly higher ( $P < 0.05$ ) in dogs fed lutein than in unsupplemented animals. Lutein supplementation did not influence concentrations of plasma retinol and  $\alpha$ -tocopherol. Concentrations of these vitamins across all treatments and all periods averaged  $3.63 \pm 0.14$  and  $37 \pm 2$   $\mu\text{mol/L}$ , respectively.

### Delayed-type hypersensitivity response

During all periods studied, DTH response to saline was low (3 to 10 % increase in skin thickness) and did not differ significantly among treatment groups. Prior to lutein feeding (week 0), DTH responses to PHA and vaccine were similar across all dietary groups. Irrespective of treatment period, maximal DTH response to PHA was observed around 24 h post-injection whereas maximal response to vaccine occurred between 48 and 72 h. Also, skin thickness response to PHA was approximately two times higher than to vaccine.

On week 6, there was a dose-related DTH response to PHA at 24 h post-injection as shown in Fig. 2. The DTH response decreased by 48 and 72 h and no significant treatment difference was observed during these times. The DTH response to vaccine was dose-related at 48 and 72 h post-injection and was not significant at 24 h.

On week 12, there was a general dose-dependent increase in DTH response to PHA at 24, 48 and 72 h as shown in Fig. 3; however, the response was significantly higher for dogs fed 20 mg lutein compared to unsupplemented dogs. In contrast to week 6, there was no significant dietary effect on DTH response to vaccine.

### Mitogen-induced PBMC proliferation

Dietary lutein did not significantly influence spontaneous proliferation by unstimulated PBMC. There was no significant effect of dietary lutein on PHA-stimulated PBMC response on weeks 0 and 4 as shown in Fig. 4. However, proliferative response was enhanced ( $P < 0.01$ ) on weeks 8 (10  $\mu\text{g/mL}$  PHA) and 12 (2 and 10  $\mu\text{g/mL}$  PHA) in dogs fed 20 mg lutein compared to unsupplemented dogs. Dogs fed 5 and 10 mg lutein also had higher PBMC proliferation on week 8 in response to 10  $\mu\text{g/mL}$  PHA.

The effects of dietary lutein on Con A-stimulated PBMC proliferative response (see Figure 5) were generally similar to those observed with PHA-induced proliferation. On weeks 8 and 12, dogs fed 20 mg lutein had higher PBMC proliferation in response to both concentrations of Con A. Dogs fed 10 mg lutein also showed higher PBMC proliferation on weeks 8 and 12 in response

to 5 µg/mL Con A. Generally, PBMC proliferation was higher with 5 µg/mL than with 1 µg/mL Con A.

Proliferation of PBMC in response to PWM (Figure 6) was generally similar to those observed with PHA and Con A. Dogs fed 20 mg lutein had significantly higher PBMC proliferation on week 8 and 12 in response to both concentrations of PWM as compared to unsupplemented controls. Those fed 10 mg lutein also had higher proliferative response on week 8. Again, no significant treatment difference was observed at weeks 0 and 4.

#### Natural killer cell cytotoxic activity

Dietary lutein supplementation did not significantly influence NK cell cytotoxic activity. Specific lysis of target cells by PBMC averaged  $49.1 \pm 1.1$  % across all treatments and sampling periods.

#### Lymphocyte subpopulations

The effects of dietary lutein on the percentages of CD5+, CD4+, CD8+, CD21+ (B cells) and MHC class II lymphocyte subpopulations are illustrated in Figures 7 and 8. Prior to dietary lutein supplementation (week 0), there were no significant differences in the percentages of any of the lymphocyte markers. On week 12, % CD4+ cells was higher in dogs fed 5 and 10 mg lutein whereas the CD8+ population was not influenced by the diet (Figure 7). On the other hand, dogs fed 20 mg lutein had significantly higher % CD8+ T cytotoxic cells on week 8 compared to control. The ratio of CD4:CD8 was similar among treatments on weeks 0, 4 and 8 but tended to be higher ( $P < 0.08$ ) in dogs fed 10 mg ( $2.50 \pm 0.16$ ) compared to control ( $2.10 \pm 0.16$ ).

On weeks 4 and 8, dogs fed lutein generally had higher percentages of CD5+ cells than unsupplemented controls and was statistically significant with dogs fed 5 and 20 mg lutein (Figure 8). Dogs fed 20 mg lutein also had elevated % MHC class II cell populations on week 8 and 12 compared to unsupplemented dogs (Figure 8). Dogs fed lower amount of lutein had MHC class II populations similar to control.

In contrast to other lymphocyte subpopulations, dietary lutein did not significantly influence the CD21+ B cell population.

#### Interleukin-2 production

The production of IL-2 by PHA-stimulated PBMC in whole blood cultures did not differ significantly among dietary treatments throughout the experimental period. Concentrations of IL-2 in culture medium averaged  $15.7 \pm 0.4$  ng/mL throughout the study.

#### Immunoglobulin production

Plasma IgG concentrations tended to increase ( $P > 0.05$ ) throughout the 17-week sampling period as illustrated in Fig. 9. Concentrations were similar among dietary treatments during the first 12 weeks of dietary supplementation. However, after revaccination on week 15, plasma IgG was higher ( $P < 0.05$ ) on week 16 in dogs fed 5 mg lutein ( $P < 0.05$ ) and on week 17 in dogs fed 20 mg lutein whereas the concentration of plasma IgM was not changed (Fig. 9).

#### Lipid peroxidation

Lutein supplementation did not significantly affect plasma TBARS activity which averaged  $95.8 \pm 0.1$  nmol MDA/L across all treatments and periods.

#### Discussion

The results show that dietary lutein significantly enhances cell-mediated immune response in the dog. Lutein supplementation stimulated the proliferative response of PBMC to PHA, Con A and PWM. There was a marked increase in PBMC proliferation in response to PHA and Con A at week 12 in dogs fed 20 mg lutein.

The data shows that enhanced mitogenesis by dietary lutein is likely attributed to increased population of lymphocytes. Dogs supplemented with lutein had higher populations of CD5+ and CD4+ cells. Dietary lutein may specifically act on T lymphocytes because no changes in B cell population were observed with lutein supplementation.

The data also showed that lutein supplementation significantly increased PWM-induced PBMC proliferation at weeks 8 and 12.

Dietary lutein also significantly increased the DTH response to vaccine, which is indicative of a specific immune response. While not wishing to be bound by any particular theory, this heightened DTH response may be explained through an increased population of MHC class II cells responsible for antigen processing and presentation. Lutein supplementation significantly increased the number of cells stained positive for MHC class II molecules compared to unsupplemented dogs.

Lutein did not significantly affect polyclonal antibody (IgG and IgM) production ex vivo in the canine during the first 12 weeks of supplementation. However, upon reexposure to the antigen, plasma IgG concentrations increased in lutein fed dogs, suggesting an anamnestic effect of dietary lutein in increasing the memory B cells' ability to secrete IgG.

In summary, dietary lutein enhanced canine T-helper cell population and the expression of MHC class II molecules, resulting in increased mitogen-induced canine PBMC proliferation and DTH response. Also, lutein is believed to increase Ig production.

#### Example 2 - Lutein Uptake in Cats.

Fifty-six female Tabby cats (10 months old) were randomly assigned to be fed 0, 1, 5, or 10 mg lutein daily for 12 weeks. The lutein contained 76.66% lutein and 5.23% zeaxanthin and was incorporated into the basal diet (see Table 3) to a final concentration of 250 mg lutein/kg of diet.

Table 3

Component	Composition (g/kg)
Moisture	72
Protein	310
Ash	52
Fat	217
Crude fiber	14
Calcium	11.5
Phosphorus	8.3
Gross Energy (kcal/kg)	5412

Prior to being fed to the cats, the lutein-containing diet was mixed with additional basal diet to achieve the desired lutein concentration. The final diets were mixed weekly and stored at -20°C in sealed containers under nitrogen gas. Prepared food analyzed periodically showed no significant destruction of lutein. Food and water were available ad libitum. Cats were housed (7 cats/pen; 1.5 x 5.0 m) in a temperature (20 to 22°C) and light (14 h light) controlled facility.

Blood was collected by jugular venipuncture into heparinized evacuated tubes on weeks 0, 2, 4, 8 and 12 and aliquots used for HPLC analysis and for assessing immune responses.

#### Extraction of plasma for HPLC

Plasma lutein, retinol and  $\alpha$ -tocopherol were analyzed by reverse phase HPLC. Briefly, plasma protein was precipitated with an equal volume of ethanol containing 0.1% butylated hydroxytoluene (BHT) (Aldrich Chemical Co., Milwaukee, WI). The mixture was extracted with 5 ml of a 1:1 mixture of petroleum ether:anhydrous diethyl ether and the dried residue resuspended in mobile phase. The mobile phase was a mixture of acetonitrile, methanol and chloroform (47:47:6, v/v/v). The internal standard used was retinyl acetate (Sigma Chem. Co.,



St. Louis, MO). Samples were eluted on a 5  $\mu$ m C18 reverse phase column (3.9 x 150 mm; Resolve, Millipore Corp., Milford MA) with a flow rate of 1.0 ml/min. The identity of the eluted compounds was verified by comparing their absorption spectra with those of standard compounds.

## 5 Delayed type hypersensitivity (DTH)

The DTH response was evaluated on week 0, 6, and 12 after the initiation of lutein feeding. Cats were mildly sedated with an i.m. injection of ketamine hydrochloride (5 mg/kg; Fort Dodge, IA) and acepromazine (0.1 mg/kg; Vedco, St. Joseph, MO). The hair on the flank was clipped and the area wiped with 70% ethyl alcohol. All cats were injected i.d. with 100  $\mu$ l of saline (8.5 g/L; control), concanavalin A (Con A; 0.5 g/L) to measure nonspecific immunity, and with an attenuated polyvalent vaccine (Felocell, Pfizer, NY, NY) containing feline herpesvirus-1, feline calicivirus, feline parvovirus and Chlamydia psittaci to measure specific immunity. The DTH response was assessed by measuring skin induration at 24, 48 and 72 h after injection with the aid of a digital micrometer (Mitsutoyo, Tokyo, Japan). The response was expressed as a percentage of skin thickness measured at the same injection site at 0 h.

## 15 Peripheral blood mononuclear cell proliferation

Whole blood was used to analyze the mitogenic proliferative responsiveness of peripheral blood mononuclear cells (PBMC) to phytohemagglutinin (PHA), Con A and pokeweed mitogen (PWM) in order to mimic in vivo conditions. Heparinized whole blood was diluted 1:12 with RPMI-1640 containing 25 mM of Hepes, penicillin (100 U/mL) and streptomycin (100  $\mu$ g/mL) (Sigma, St. Louis, MO) (hereafter termed complete medium). Preliminary studies using undiluted blood and blood diluted 1:2, 1:4, 1:8, 1:12 and 1:16 showed optimal repeatability and response to mitogens with the 1:12 dilution. The mitogens were used at the following final concentrations previously determined to provide both maximal (the higher mitogen concentration) and suboptimal (the lower mitogen concentration) proliferation: PHA (1.25 and 0.25  $\mu$ g/mL), Con A (2.5 and 0.5  $\mu$ g/mL) or PWM (0.125 and 0.025  $\mu$ g/mL). Tritiated thymidine uptake was

measured by liquid scintillation and PBMC proliferation response was expressed as cpm of stimulated cultures corrected for cpm of unstimulated cultures.

### Lymphocyte subpopulations

Blood leukocytes were separated on Histopaque-1119 (Sigma, St. Louis, MO) and cells washed three times with phosphate-buffered saline (PBS, pH 7.4). Contaminating RBC were lysed with  $\text{NH}_4\text{Cl}$  (8.4 g/L) and cell viability determined by trypan blue exclusion. Lymphocyte subsets were determined by FACScan flow cytometry (Becton Dickinson, San Jose, CA) immediately after cell preparation. Isolated PBMC were resuspended to  $1 \times 10^7$  cells/mL phosphate buffered saline (PBS) supplemented with 2% gamma globulin-free serum, 5% goat serum and 0.2 g/L sodium azide (Baker, Phillipsburg, NJ). For immunofluorescence analysis,  $5 \times 10^5$  cells were incubated for 30 minutes on ice with a previously determined optimal concentration of mouse anti-cat primary monoclonal antibody. The antibodies were specific for the following lymphocyte subsets: total T cells (anti-CD3), T-helper cells (anti-CD4), T cytotoxic/suppressor cells (anti-CD8), lymphocytes expressing major histocompatibility complex (MHC) class II antigens (anti-MHC class II), and B cells (anti-CD21). Cells were then washed three times and incubated with a secondary antibody, fluorescein isothiocyanate (FITC)-conjugated goat F(ab')<sub>2</sub> anti-mouse IgG (H+L) (Caltag, Burlingame, CA) for 30 minutes on ice to visualize the bound antibody. Stained cells were fixed in 4% paraformaldehyde in preparation for acquisition. Appropriate negative controls were included to correct the level of background fluorescence. Fluorescence analysis was performed on lymphocytes gated by forward and side scatter. Data were expressed as a percentage of positive-staining cells corrected for cells stained nonspecifically with the secondary antibody.

### NK cytotoxicity assay

The Crandell feline kidney fibroblast was used as the target cell. Target cells were resuspended to  $2 \times 10^5$  cells/mL and triplicate 100  $\mu\text{L}$  aliquots were pipetted into a 96-well U-bottom plate (Costar, Cambridge, MA) and cells allowed to adhere. Isolated PBMC (effector

cells) were then added to the target cells to achieve effector:target cell (E:T) ratios of 25:1, 12.5:1 and 6.25:1. The cell mixture was incubated for 8 hours after which 100  $\mu$ L Rose Bengal (2.5 g/L in PBS; Sigma, St. Louis, MO) were added and incubated at room temperature for 5 minutes. Optical density was measured at 550 nm using an ELISA plate reader. The percentage of NK-specific lysis was calculated as follows:

$$\text{Specific cytotoxicity (\%)} = 100 \times \{1 - [(\text{OD of target cells and effector cells} - \text{OD of effector cells}) / (\text{OD of target cells})]\}$$

### IL-2 production

Whole blood was diluted 1:2 in RPMI-1640 complete medium and cultured for 48 hours in the presence of 5  $\mu$ g/mL Con A. The conditioned medium was removed and frozen at -80°C. The IL-2 concentrations were determined in duplicate by ELISA using a human IL-2 kit (InterGen, Purchase, NY). The human anti-IL-2 was previously determined to cross-react with feline IL-2.

### Serum IgG

Serum IgG concentration was determined by single radial immunodiffusion (SRID). Goat antiserum to cat IgG (15%, whole molecule) (Sigma, St. Louis, MO) was incorporated into agarose (10 g/L in PBS; Sigma, St. Louis, MO). The loading volume for the test serum and standard was 5  $\mu$ L and the plates were incubated for 24 hours in a humidified chamber. Ring diameters were measured using a SRID reader (Transidyne General Corp., Ann Arbor, MI).

### Lipid peroxidation (TBARS)

Lipid peroxidation was assessed by the TBARS (thiobarbituric acid-reactive substances) assay on plasma collected on weeks 0, 2, 4, 8 and 12. Duplicate 500  $\mu$ L of cat plasma was boiled for 45 minutes with 3 mL of phosphoric acid (10 g/L) and 1 mL of TBA (6 g/L). After cooling, the TBA-MDA (malondialdehyde) complex was extracted with 4 mL of n-butanol. The butanol layer was separated by centrifugation (1,000 x g for 10 minutes) and absorbance read (Beckman,

Fullerton, CA) at 532 nm. The absorbance unit was converted to nmoles MDA from a standard curve generated with a 1,1,3,3,-tetramethoxypropane (TMP) (Sigma, St. Louis, MO).

### Statistics

Data were analyzed by split-plot ANOVA using the General Linear Model of SAS (Statistical Analysis System). The statistical model was  $Y_{ijk} = \mu + \text{Treatment}_i + \text{Cat}_j(\text{Treatment}_i)$  (subplot error term to be used to test the effects of treatment) +  $\text{Sampling period}_k + \text{Treatment}_i * \text{Period}_k + e_{ijk}$ . Differences between treatment means within a sampling period were compared using orthogonal contrast. Differences with  $P < 0.05$  were considered as statistically significant.

## RESULTS

### Body weight and food intake

Dietary lutein did not significantly affect changes in body weight during the experimental period (data not shown). Body weight across all diets and periods averaged  $1.41 \pm 0.04$  kg. Average daily food intake was 83.2 g across the study period and was not significantly different among treatments.

### Plasma lutein

Prior to lutein supplementation, the baseline plasma lutein concentration averaged  $0.036 \pm 0.005$   $\mu\text{mol/L}$  in all cats. Lutein concentrations in unsupplemented cats remained at this concentration throughout the study period. Plasma lutein increased in a dose-dependent manner between week 2 and 12 as shown in Fig. 10. Lutein concentrations in lutein-fed cats increased rapidly on week 2 and concentrations continued to increase, albeit more gradually, through week 12 in cats fed 5 or 10 mg lutein. Lutein supplementation did not influence the concentration of plasma retinol and  $\alpha$ -tocopherol which averaged  $0.56 \pm 0.03$  and  $14.9 \pm 0.9$   $\mu\text{mol/L}$ , respectively.

### Mitogen-induced PBMC proliferation

Dietary lutein did not significantly influence spontaneous proliferation by unstimulated PBMC and averaged  $1,744 \pm 147$  cpm throughout the study. Cats fed 10 mg lutein showed significantly higher PBMC proliferative response to Con A ( $2.5 \mu\text{g/mL}$ ) at week 4 but treatment differences were not observed on week 8 and 12 (see Fig. 11). No significant treatment difference was observed with a suboptimal dose ( $0.5 \mu\text{g/mL}$ ) of Con A. There were no significant dietary effects on PHA-induced PBMC proliferation throughout the study. Tritiated thymidine uptake with  $1.25$  and  $0.25 \mu\text{g/mL}$  PHA averaged  $6,464 \pm 504$  and  $1,934 \pm 147$  cpm, respectively. Of the 3 mitogens used, PWM produced the highest proliferation (Figure 12). Lutein supplemented generally increased PBMC proliferation on week 4; differences were significant when cultures were stimulated with  $0.125 \mu\text{g/mL}$  (1 and 10 mg lutein) and  $0.025 \mu\text{g/mL}$  (1 mg lutein) of PWM.

### Delayed-type hypersensitivity (DTH)

Prior to lutein supplementation, no significant differences were observed in DTH response among dietary treatments (data not shown). The DTH response to saline was low (averaged  $4.3 \pm 0.6\%$ ) and not significantly different among treatments during all periods studied. On week 6, no significant dietary effect on DTH response to Con A was observed (Fig. 13). However, by week 6 of lutein feeding, there was a significant dose-related DTH response to vaccine when measured at 72 h post-injection; response was significantly higher with cats fed 5 or 10 mg lutein. By week 12, no significant treatment difference was observed with both Con A and vaccine (Fig. 14); however, the same general trend in a dose-related DTH response persisted with vaccine on week 12 at 72 h postinjection as was observed on week 6.

In general, peak DTH response to Con A was observed around 24 h post-injection whereas maximal response to vaccine occurred between 48 and 72 h.

Natural killer (NK) cell activity

Cytotoxicity activity of NK cells at effector:target cell (E:T) ratios of 6.25:1, 12.5:1 and 25:1 are illustrated in Table 4.

Table 4

Natural killer (NK) cell activity (% specific lysis) of isolated PBMC in cats fed daily with 0, 1, 5, or 10 mg lutein<sup>1</sup>

		Dietary lutein (mg/d)			
Week		0	1	5	10
<u>Effector: Target ratio of 6.25:1</u>					
10	0	18.4 ± 6.1 <sup>a</sup>	19.8 ± 5.5 <sup>a</sup>	17.1 ± 5.8 <sup>a</sup>	22.8 ± 6.5 <sup>a</sup>
	4	42.8 ± 4.8 <sup>ab</sup>	46.6 ± 4.6 <sup>a</sup>	41.2 ± 5.0 <sup>ab</sup>	33.2 ± 4.8 <sup>a</sup>
	8	24.9 ± 5.3 <sup>b</sup>	28.0 ± 4.8 <sup>ab</sup>	34.3 ± 5.0 <sup>ab</sup>	41.1 ± 5.5 <sup>a</sup>
	12	26.2 ± 5.0 <sup>b</sup>	45.8 ± 5.5 <sup>a</sup>	37.4 ± 5.8 <sup>ab</sup>	39.7 ± 6.1 <sup>ab</sup>
<u>Effector: Target ratio of 12.5:1</u>					
15	0	28.5 ± 5.8 <sup>a</sup>	30.0 ± 7.0 <sup>a</sup>	20.8 ± 7.0 <sup>a</sup>	20.7 ± 8.2 <sup>a</sup>
	4	44.4 ± 5.3 <sup>a</sup>	44.1 ± 4.9 <sup>a</sup>	37.5 ± 5.1 <sup>a</sup>	33.7 ± 5.1 <sup>a</sup>
	8	33.3 ± 6.4 <sup>ab</sup>	27.4 ± 6.5 <sup>b</sup>	44.4 ± 6.2 <sup>ab</sup>	48.2 ± 6.5 <sup>a</sup>
	12	33.8 ± 6.4 <sup>a</sup>	40.5 ± 6.1 <sup>a</sup>	35.9 ± 5.8 <sup>a</sup>	38.2 ± 7.0 <sup>a</sup>
<u>Effector: Target ratio of 25:1</u>					
20	0	27.6 ± 6.1 <sup>ab</sup>	21.2 ± 6.2 <sup>ab</sup>	17.2 ± 6.3 <sup>b</sup>	38.8 ± 8.3 <sup>a</sup>
	4	39.5 ± 5.2 <sup>a</sup>	36.2 ± 4.4 <sup>a</sup>	45.0 ± 4.9 <sup>a</sup>	33.9 ± 4.6 <sup>a</sup>
	8	32.2 ± 6.7 <sup>c</sup>	44.9 ± 8.0 <sup>ab</sup>	32.6 ± 5.3 <sup>bc</sup>	47.8 ± 5.5 <sup>a</sup>
	12	34.0 ± 10.2 <sup>a</sup>	35.6 ± 6.2 <sup>a</sup>	26.9 ± 6.3 <sup>a</sup>	29.2 ± 9.5 <sup>a</sup>

<sup>1</sup>Values are presented as means ± SEM (n=14/diet/period). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, P < 0.05

No significant treatment difference in cytotoxicity was observed on week 0 prior to lutein supplementation. However, on week 8, NK cell cytotoxic activity was higher in cats fed 10 mg lutein; differences were significant with E:T ratios of 6.25:1 and 25:1. Also, cats fed 1 mg lutein also showed significantly higher cytotoxicity on week 12 (E:T of 6.25:1) and 8 (E:T of 25:1). No

significant treatment differences were observed with E:T ratio of 12.5:1 even though the same general trend was evident.

#### Lymphocyte subpopulations

Dietary lutein did not influence significantly the total number of T cells (CD3) (Figure 15) However, on week 12 of supplementation, the percentage of CD21 + B cells was significantly elevated in cats fed 10 mg lutein. Changes in the CD4+ T helper cell population (Figure 16) were similar to that of the CD21+ cells. In contrast, the percentage of CD8+ T cytotoxic cells (Figure 10), the ratio of CD4:CD8, and the percentage of MHC class II+ cells were not influenced significantly by dietary lutein in any of the time periods studied.

#### Interleukin-2 production

There were no significant differences in IL-2 production throughout the experimental period. The average concentration of IL-2 in Con A-stimulated cultures throughout the study was  $15.1 \pm 0.79$  ng/mL.

#### Antibody production

Plasma IgG concentration was not significantly different at the commencement of the study and averaged  $15.85 \pm 0.62$  mg/mL (Figure 17). However, by week 8 of lutein feeding, cats fed 1 or 10 mg lutein had significantly higher concentrations of plasma IgG. This trend persisted through week 12 where plasma IgG in cats fed 10 mg lutein remained significantly higher than unsupplemented animals.

#### Lipid peroxidation

Dietary lutein did not significantly influence plasma TBARS activity and concentrations averaged  $20.3 \pm 0.2$  nmol MDA/L across all diet groups and periods.

### Discussion

The results showed that lutein modulates immune response in the domestic cat. Cats absorb lutein into the blood and the lutein is subsequently taken up by circulating leukocytes. The results showed that the absorption of lutein is dose- and time-dependent and does not significantly alter plasma concentrations of retinol and  $\alpha$ -tocopherol.

Dietary lutein stimulated the proliferative response of PBMC to Con A and PWM. The enhanced lymphocyte proliferation by dietary lutein is most likely mediated via the alteration of cell surface marker expression on lymphocytes.

Dietary lutein also significantly increased the B and T-helper cell populations. NK cell cytotoxic activity was also enhanced by dietary lutein. Lutein is believed to upregulate NK cell activity through the activation of Th cells or its direct action on NK cells.

Dietary lutein significantly increased DTH response to vaccine in a dose-related manner at week 6. However, there was no significant boosting effect with repeated inoculation of the antigens. Even though no marked changes in total T cell population were observed, lutein supplementation significantly increased the CD4<sup>+</sup> T helper cell population but not the CD8<sup>+</sup> T cytotoxic cells. This increase in T helper cells may explain the enhanced DTH response observed in lutein-supplemented cats.

Cats fed lutein also showed significantly higher serum IgG concentrations. The observed enhancing effect of lutein on antibody production is believed to be mediated through the action of the T helper cells.

In summary, the data indicates that dietary lutein is an important immunomodulating micronutrient in the domestic cat.

While certain representative embodiments and details have been shown for purposes of illustrating the invention, it will be apparent to those skilled in the art that various changes in the methods and apparatus disclosed herein may be made without departing from the scope of the invention, which is defined in the appended claims.

What is claimed is:



## CLAIMS

1. A process for enhancing immune response and improving the overall health of a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed by said animal.

2. A process claimed in claim 1 in which said diet includes from about 1 to about 50 mg/day of lutein.

3. A process as claimed in claim 1 in which said diet includes from about 2 to about 315 mg lutein per kg of diet.

4. A process as claimed in claim 1 wherein said companion animal is a dog.

5. A process as claimed in claim 4 in which said diet includes from about 5 to about 20 mg/day of lutein.

6. A process as claimed in claim 1 wherein said companion animal is a cat.

7. A process as claimed in claim 6 in which said diet includes from about 5 to about 10 mg/day of lutein.

8. A process as claimed in claim 1 in which said diet comprises about 20 to 40% crude protein, about 4 to 30% fat, and about 4 to 20% total dietary fiber.

9. A process for increasing the lutein concentration in the circulating blood of a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed into the bloodstream of said animal.

10. A process for increasing IgG concentrations in a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed into the bloodstream of said animal.

11. A process for increasing lymphocyte cells in a companion animal comprising the step of feeding said animal a diet containing an effective amount of lutein for a time sufficient for said lutein to be absorbed into the bloodstream of said animal.

12. A supplement for enhancing immune response and improving the overall health of a companion animal comprising, on a dry matter basis, from about 0.001 to about 2% by weight lutein.

13. The supplement as claimed in claim 12 wherein said companion animal is a dog.

14. The supplement as claimed in claim 13 comprising from about 0.01% to about 1% by weight lutein.

15. The supplement as claimed in claim 12 wherein said companion animal is a cat.


16. The supplement as claimed in claim 15 comprising from about 0.01% to about 1% by weight lutein.

## ABSTRACT


A food supplement and process for feeding a companion animal such as a dog or cat a diet containing an effective amount of lutein to enhance immune response and improve the overall health of the animal is provided. Preferably, the diet includes from about 1 to about 50 mg/day of lutein (from about 2 to about 315 mg lutein/kg diet). Such a diet provides sufficient lutein to be absorbed by the animal and supplied by the blood and blood leukocytes and neutrophils in the animal.

5


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000




**Figure 1** Concentrations of plasma lutein + zeaxanthin in dogs fed diets containing 0, 5, 10 or 20 mg lutein for 12 wk. Values are means  $\pm$  SEM ( $n = 14$ ). Lutein + zeaxanthin was not detectable in unsupplemented dogs. Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ . nd = non-detectable.



**Figure 2** Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in dogs fed 0, 5, 10, or 20 mg lutein daily for 6 wk. Dogs were challenged with PHA (top panel) and a polyvalent vaccine (bottom panel) and skin induration was measured at 0, 24, 48 and 72 h post-injection. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .




**Figure 3** Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in dogs fed 0, 5, 10, or 20 mg lutein daily for 12 wk. Dogs were challenged with PHA (top panel) and a polyvalent vaccine (bottom panel) and skin induration was measured at 0, 24, 48 and 72 h post-injection. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .



**Figure 4** Incorporation of [ $^3\text{H}$ ]-thymidine by PHA-induced (10 or 2 µg/mL) PBMC in dogs fed 0, 5, 10, or 20 mg lutein daily. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly,  $P < 0.05$ .


## Concanavalin A




**Figure 5** Incorporation of [ $^3\text{H}$ ]-thymidine by Con A-induced (5 or 1 µg/mL) PBMC in dogs fed 0, 5, 10, or 20 mg lutein daily. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .




## Pokeweed Mitogen




**Figure 6** Incorporation of [ $^3\text{H}$ ]-thymidine by PWM-induced (2.5 or 0.5 µg/mL) PBMC in dogs fed 0, 5, 10, or 20 mg lutein daily. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly,  $P < 0.05$ .




**Figure 7** Percentages (calculated by expressing the number of cells that stained positive for surface marker as a percentage of total number of lymphocytes) of CD4+ T-helper (above) and T cytotoxic/suppressor CD8+ (bottom) lymphocyte subpopulations in dogs fed 0, 5, 10, or 20 mg lutein daily for 12 wk. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .




**Figure 8** Percentages (calculated by expressing the number of cells that stained positive for the cell surface marker as a percentage of total number of lymphocytes) of CD5 positive (above) and MHC class II positive (bottom) lymphocytes in dogs fed 0, 5, 10, or 20 mg lutein daily for 12 wk. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .




**Figure 9** Concentrations of plasma polyclonal IgG (above) and IgM (bottom) in dogs fed 0, 5, 10, or 20 mg lutein daily for 17 wk. All dogs were vaccinated with a polyclonal vaccine on wk 13 and 15. Values are means  $\pm$  SEM ( $n = 14$  dogs/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .



**Figure 10** Concentrations of plasma lutein from cats fed diets containing 0, 1, 5 or 10 mg lutein for 12 wk. Values are means  $\pm$  SEM ( $n = 14$  cats/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly,  $P < 0.05$ .




**Figure 11** Incorporation of [<sup>3</sup>H]-thymidine by Con A-induced (2.5 or 0.5 µg/mL) PBMC from cats fed 0, 1, 5, or 10 mg lutein daily. Values are means ± SEM (n = 14 cats diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly, *P* < 0.05.




**Figure 12** Incorporation of [ $^3\text{H}$ ]-thymidine by PWM-induced (0.125 or 0.025  $\mu\text{g/mL}$ ) PBMC from cats fed 0, 1, 5, or 10 mg lutein daily. Values are means  $\pm$  SEM ( $n = 14$  cats/diet). Data were analyzed by repeated measures ANOVA. Means within a period with different superscripts differ significantly,  $P < 0.05$ .

## Week 6




**Figure 13** Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in cats fed 0, 1, 5, or 10 mg lutein daily for 6 wk. Values are means  $\pm$  SEM ( $n = 14$  cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ . Cats were challenged with Con A (top panel) and a polyvalent vaccine (bottom panel) and skin induration measured at 0, 24, 48 and 72 h post-injection.







**Figure 4** Delayed-type hypersensitivity response (expressed as a percentage of skin thickness measured at 0 h) in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means  $\pm$  SEM ( $n = 14$  cats/diet). Data were analyzed by repeated measures ANOVA. There was no significant difference among treatments at all sampling periods. Cats were challenged with Con A (top panel) and a polyvalent vaccine (bottom panel) and skin induration measured at 0, 24, 48 and 72 h post-injection.



**Figure 15** Percentages (calculated by expressing the number of cells that stained positive for the cell surface marker as a percentage of total number of lymphocytes) of CD3 positive (Total T cells, above) and CD21 positive (B cells, bottom) lymphocytes in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means  $\pm$  SEM ( $n = 14$  cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .



**Figure 10** Percentages (calculated by expressing the number of cells that stained positive for surface marker as a percentage of total number of lymphocytes) of CD4+ T-helper (above) and CD8+ T-cytotoxic/suppressor (bottom) lymphocyte subpopulations in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means  $\pm$  SEM ( $n = 14$  cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .



**Figure 17** Concentrations of plasma polyclonal IgG in cats fed 0, 1, 5, or 10 mg lutein daily for 12 wk. Values are means  $\pm$  SEM ( $n = 14$  cats/diet). Data were analyzed by repeated measures ANOVA. Means within a sampling period with different superscripts differ significantly,  $P < 0.05$ .

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the invention entitled:

**LUTEIN-CONTAINING SUPPLEMENT AND PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS (Docket IAM 467 PA), described and claimed**

XX in the attached specification;  
 \_\_\_\_\_ in the specification filed \_\_\_\_\_  
 as U.S. Application Serial No. \_\_\_\_\_, and as amended \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims as filed and as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under 35 USC § 119(e) of any United States provisional application(s) listed below:

Application Number	Filing Date
<u>60/081,968</u>	<u>April 16, 1998</u>

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Richard A. Killworth	Reg. No. 26,397
James F. Gottman	Reg. No. 27,262
Timothy W. Hagan	Reg. No. 29,001
Richard C. Stevens	Reg. No. 28,046
Robert L. Showalter	Reg. No. 33,579
James E. Beyer	Reg. No. 38,564
Susan M. Luna	Reg. No. 38,769
Carolyn M. Sloane	Reg. No. 44,339
Daniel C. Stelter	Reg. No. 40,830

Address all telephone calls to (937) 223-2050. Address all correspondence to: KILLWORTH, GOTTMAN, HAGAN & SCHAEFF, L.L.P., One Dayton Centre, One South Main Street, Suite 500, Dayton, Ohio 45402-2023.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or first Inventor: Michael G. Hayek

Inventor's signature Michael G. Hayek

Date: April 8, 1999

Residence: 926 Tammy Circle  
Dayton, Ohio 45415-2136

Citizenship: U.S.A.

Post Office Address: c/o The Iams Company  
7250 Poe Avenue  
Dayton, Ohio 45414